# Geneyx Genomex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/geneyx-genomex

- Industry: Biotechnology
- Headquarters: Herzliya, Israel
- Website: www.geneyx.com
- Total disclosed funding: $7.9M
- Latest round: Seed (Nov 9, 2021)
- Investors on record: 5

## About

Geneyx Genomex, Ltd. specializes in AI-driven genetic data analysis and interpretation, focusing on next-generation sequencing technologies to enhance clinical genomics and patient care through innovative software solutions.Founded in 2018 in Herzliya, Israel, Geneyx Genomex, Ltd. provides a platform for genetic data analysis and interpretation. The company was co-founded by David Yizhar, Dvir Dahary, Ofer Barnea, and Raviv Itzhaky. In November 2021, they secured USD 6.5 mn in Seed funding co-led by Accenture Technology Ventures and Capri Ventures, bringing their total funding to USD 6.5 mn. Geneyx has completed a total of 4 deals, with the most recent deal occurring on November 9, 2021.Geneyx offers a comprehensive platform for AI-based genetic data analysis, focusing on next-generation sequencing (NGS) technologies. Their core product is the Geneyx Analysis platform, which integrates DNA and RNA sequencing data analysis, facilitating precise workflows in clinical genomics. Launched in 2018, it serves hospitals, genetics labs, and life-science companies, with applications in pharmacogenomics and carrier screening. The platform is utilized in over 190 hospitals and labs across 50 countries, including key markets in North America, Europe, and the Asia-Pacific region.Geneyx generates revenue through a subscription model for its Geneyx Analysis platform, serving healthcare providers and genetics laboratories. Clients engage in contracts that grant access to the platform’s features, including automated updates and customizable reports, resulting in a reported diagnostic yield increase of over 65%. Pricing is tailored to the specific needs and features selected by clients, reflecting the platform’s role in advancing genomic analysis within clinical settings.Following the recent Seed funding of USD 6.5 mn in November 2021, Geneyx plans to accelerate the global adoption of its AI-based genomic interpretation technology. The funding will support initiatives to leverage insights from genetic data worldwide, enhancing clinical research and pharmaceutical discovery. Future growth will focus on expanding into new markets, though specific regions and product launches have not been detailed.

## Funding rounds

- Seed, Nov 9, 2021, $6.5M — Accenture Technology Ventures, Capri Ventures
- Seed, Aug 28, 2020, $0.5M — Magna Capital
- Seed, Mar 1, 2020, $0.9M — German Dive Digital, NextLeap Ventures

## Investors

- German Dive Digital — Seed
- NextLeap Ventures (https://capitalatlas.ai/funds/nextleap-ventures) — Seed
- Magna Capital (https://capitalatlas.ai/funds/magna-capital) — Seed
- Accenture Technology Ventures (https://capitalatlas.ai/funds/accenture-technology-ventures) — Seed
- Capri Ventures (https://capitalatlas.ai/funds/capri-ventures) — Seed